David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
R-CODOX-M/R-IVAC versus DA-EPOCH-R bij nieuw gediagnosticeerd burkittlymfoom
jan 2024 | Lymfoom